History
# Registration date Revision Id
3 2023-09-27, 1402/07/05 284666
2 2023-03-29, 1402/01/09 260076
1 2022-09-04, 1401/06/13 238930
Changes made to previous revision
This is the first revision

Protocol summary

Study aim
Investigation the effect of 25-hydroxy vitamin D3 (25OHD3) serum level on anxiety and depression in colorectal adenocarcinoma patients.
Design
A four arm parallel group non-randomised non-blinded before-after designed clinical trial without control group, 60 patients enrolled between march 2023 and march 2024.
Settings and conduct
In this trial 60 new cases referred to the Reza Radiotherapy Center will be included in based on criteria. Pearls of 5000 units of cholecalciferol of Zahravi Pharmaceutical Company are given based on the serum 25OHD3 level of intervention groups, meaured by enzyme-linked immunosorbent assay in Central Jihad University Laboratory, according to the following instructions for 3 months: D: daily, I: every 5 days, B: every 7 days, S: every 10 days. Patients will fill out Zung's Self-rating anxiety Scale (S.A.S) and Zung's Self-rating depression Scale (S.D.S) questionnaires before and after the intervention, and their serum 25OHD3 will be measured monthly.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Age 18-65 years old; Ability to write and read in Persian; Ability to answer questionnaire questions.Exclusion criteria: Complicated dibetes or hypertension; History of visiting a psychiatrist or psychologist in the last 6 months or taking psychotropic drugs in the last 6 months؛ Pregnancy; Breastfeeding; Taking vitamin D or vitamin D3 analogs in the last 3 months; Vitamin D serum level more than 100 ng/ml; Serum level of ionized calcium more than 5.6 mg/dL.
Intervention groups
Deficiency group (D): 25OHD3 serum level below 12 ng/ml; Insufficiency group (I): 25OHD3 serum level 12-20 ng/ml; Borderline group (B): 25OHD3 serum level 20-30 ng/ml; Sufficient group (S): 25OHD3 serum level above 30 ng/ml
Main outcome variables
Zung S.D.S score; Zung S.A.S score; 25OHD3 serum level before intervention; 25OHD3 serum level after the end of intervention

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20220609055113N1
Registration date: 2022-09-04, 1401/06/13
Registration timing: prospective

Last update: 2022-09-04, 1401/06/13
Update count: 2
Registration date
2022-09-04, 1401/06/13
Registrant information
Name
Reyhaneh Entezari heravi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 51 3765 8488
Email address
r.entezari98@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-03-08, 1401/12/17
Expected recruitment end date
2024-03-08, 1402/12/18
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of the effect of serum vitamin D levels on anxiety and depression in patients with colorectal adenocarcinoma
Public title
"Effect of vitamin D on anxiety and depresion of patients with colorectal cancer"
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion criteria:
Ability to read and write in Persian Ability to answer questionnaire questions
Exclusion criteria:
Complicated diabetes or hypertension History of visiting a psychiatrist or psychologist in the last 6 months or taking psychotropic drugs in the last 6 months Pregnancy Breastfeeding Taking vitamin D or vitamin D3 analogs in the last 3 months Vitamin D serum level more than 100 ng/ml Serum level of ionized calcium more than 5.6 mg/dL
Age
From 18 years old to 65 years old
Gender
Both
Phase
2
Groups that have been masked
No information
Sample size
Target sample size: 60
Randomization (investigator's opinion)
N/A
Randomization description
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Islamic Azad University of Mashhad Medical Sciences Branch
Street address
NO. 181 , Resalat 7., Faramarz Abbasi 3., Faramarz Abbasi blvd.
City
Mashhad
Province
Razavi Khorasan
Postal code
9196111111
Approval date
2022-08-15, 1401/05/24
Ethics committee reference number
IR.IAU.MSHD.REC.0000.000

Health conditions studied

1

Description of health condition studied
Anxiety
ICD-10 code
F41.9
ICD-10 code description
Anxiety disorder, unspecified

2

Description of health condition studied
Depression
ICD-10 code
F32.9
ICD-10 code description
Major depressive disorder, single episode, unspecified

Primary outcomes

1

Description
Depression score in Zung questionnaire
Timepoint
Before starting intervention, 90 days after starting to take cholecalciferol
Method of measurement
Zung Self-Rating Depression Scale questionnaire

2

Description
Anxiety score in Zung questionnaire
Timepoint
Before starting intervention, 90 days after starting to take cholecalciferol
Method of measurement
Zung Self-Rating Depression Scale qestionnaire

3

Description
Serum level of 25-hydroxy vitamin D3
Timepoint
Before starting the intervention and 30, 60 and 90 days after starting cholecalciferol
Method of measurement
enzyme-linked immunosorbent assay

Secondary outcomes

empty

Intervention groups

1

Description
The first intervention group: patients with a serum level of 25-hydroxyvitamin D3 less than 12 ng/ml receive a total of 85 pearls of 5000 units of cholecalciferol from Zahravi Pharmaceutical Company, one pearl per day for 3 months.
Category
Treatment - Drugs

2

Description
The second intervention group: patients with a serum level of 25-hydroxyvitamin D3 of 12-20 ng/ml receive a total of 18 pearls of 5000 units of cholecalciferol from Zahravi Pharmaceutical Company, one pearl every 5 days for 3 months.
Category
Treatment - Drugs

3

Description
The third intervention group: patients with a serum level of 25-hydroxyvitamin D3 of 20-30 ng/ml will receive a total of 14 pearls of 5000 units of cholecalciferol from Zahravi Pharmaceutical Company, one pearl every 7 days for 3 months.
Category
Treatment - Drugs

4

Description
The fourth intervention group: patients with a serum level of 25-hydroxyvitamin D3 above 30 ng/ml will receive a total of 11 pearls of 5000 units of cholecalciferol from Zahravi Pharmaceutical Company, one pearl every 10 days for 3 months.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Reza Radiotherapy and Oncology Center
Full name of responsible person
Mahdieh Dayani
Street address
Reza Radiotherapy and Oncology Center, 19 Rafsanjani St., Haftom Azar Sq., Rafsanjani Hwy., International Fair Blvd., Mashhad, IRAN
City
Mashhad
Province
Razavi Khorasan
Postal code
9184166759
Phone
+98 51 3500 8000
Fax
+98 51 3522 5671
Email
Info@rroc.ir
Web page address
https://www.rroc.ir/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Islamic Azad University
Full name of responsible person
Vahid Pouresmaeil
Street address
Faculty of Medicine, Azad University of Mashhad,14th Imam Khomeini St., 14th Imam Khomeini St., Imam Khomeini Blvd.
City
Mashhad
Province
Razavi Khorasan
Postal code
9133735971
Phone
+98 51 3225 0041
Email
v.pouresmaeil@mshdiau.ac.ir
Web page address
https://mashdms.iau.ir/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Islamic Azad university, Mashhad medical science branch, Dr. Mohammad shahinfar medical school
Proportion provided by this source
10
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

2

Sponsor
Name of organization / entity
Central Jihad University Laboratory
Full name of responsible person
Reyhaneh Entezari heravi
Street address
Razi Jihad Academic Medical Complex, West Razi St, Between Dah-e-dey and Imam khomeini Sq, Razi St
City
Mashhad
Province
Razavi Khorasan
Postal code
9137844955
Phone
+98 51 3854 0000
Email
info.complex@jdm.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Central Jihad University Laboratory
Proportion provided by this source
42
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

3

Sponsor
Name of organization / entity
Zahravi Pharmaceutical Company
Full name of responsible person
Farhad Kiafar
Street address
No. 23, Darou pakhsh Ave, 18th km Tehran-karaj Makhsous Road,  Alborz- Iran.
City
Tehran
Province
Tehran
Postal code
1397116441
Phone
+98 21 4499 1893
Email
info@zahravipharma.com
Web page address
http://www.zahravi.com/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Zahravi Pharmaceutical Company
Proportion provided by this source
5
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other

4

Sponsor
Name of organization / entity
Reza Radiotherapy and Oncology Center
Full name of responsible person
Mahdieh Dayani
Street address
Reza Radiotherapy and Oncology Center, 19 Rafsanjani St., Haftom Azar Sq., Rafsanjani Hwy., International Fair Blvd., Mashhad, IRAN
City
Mashhad
Province
Razavi Khorasan
Postal code
9184166759
Phone
+98 51 3500 8000
Email
Info@rroc.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Reza Radiotherapy and Oncology Center
Proportion provided by this source
5
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other

Person responsible for general inquiries

Contact
Name of organization / entity
Islamic Azad University
Full name of responsible person
Reyhaneh Entezari heravi
Position
Medical student
Latest degree
A Level or less
Other areas of specialty/work
General Practitioner
Street address
Unit 181, resalat, 7th ALLEY ,No. 3, Faramarz abbasi Ave, Faramarz abbasi Blvd, mashhad city
City
Mashhad
Province
Razavi Khorasan
Postal code
9196111111
Phone
+98 51 3765 8488
Fax
Email
r.entezari98@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Islamic Azad University
Full name of responsible person
Reyhaneh Entezari heravi
Position
Medical student
Latest degree
A Level or less
Other areas of specialty/work
General Practitioner
Street address
Unit 181, resalat, 7th ALLEY ,No. 3, Faramarz abbasi Ave, Faramarz abbasi Blvd, mashhad city
City
Mashhad
Province
Razavi Khorasan
Postal code
9196111111
Phone
+98 51 3765 8488
Fax
Email
r.entezari98@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Islamic Azad University
Full name of responsible person
Reyhaneh Entezari heravi
Position
Medical student
Latest degree
A Level or less
Other areas of specialty/work
General Practitioner
Street address
Unit 181, resalat, 7th ALLEY ,No. 3, Faramarz abbasi Ave, Faramarz abbasi Blvd, mashhad city
City
Mashhad
Province
Razavi Khorasan
Postal code
9196111111
Phone
+98 51 3765 8488
Fax
Email
r.entezari98@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
Only part of the data can be shared, such as information about the main outcome or the like.
When the data will become available and for how long
The access period starts 6 months after the results are published.
To whom data/document is available
It will be available only to researchers working in academic and scientific institutions.
Under which criteria data/document could be used
Based on the criteria of the Ministry of Health, Treatment and Medical Education about clinical trial studies.
From where data/document is obtainable
E-mail: r.entezari.iaum@gmail.com
What processes are involved for a request to access data/document
After obtaining permission from the supervisor, the information will be sent by email.
Comments
Loading...